Biohaven Stock Drops After FDA Holds Enrollment In $350M Epilepsy Drug Trials
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million deal.
BiohavenFDAXenon
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.”
IBD — Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback“The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from rodent tests, dealing a blow to an asset covered by a pending $350 million deal.”
fierce biotech — <a href="/biotech/biohaven-drug-suffers-fda-hold-days-after-attracting-350m-deal" hreflang="en">Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal</a>